Find clinical trials for Non-Hodgkin Lymphoma in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Hanyang, Seoul, KOR:
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...
Phase 1
Seoul, Korea, Republic of and 20 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Seoul, Korea, Republic of and 89 other locations
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in...
Phase 1
Seoul, Korea, Republic of and 9 other locations
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....
Phase 1, Phase 2
Seoul, Seoul, South Korea
JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...
Phase 1
Seoul, Korea, Republic of and 27 other locations
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Seoul, Korea, Republic of and 60 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 74 other locations
receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non...
Phase 1
Seoul, Korea, Republic of and 25 other locations
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...
Phase 1
Seoul, Korea, Republic of and 18 other locations
bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...
Phase 1
Seoul, Korea, Republic of and 28 other locations
Clinical trials
Research sites
Resources
Legal